The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An independent, external validation study of proposed genetic biomarkers of irinotecan toxicity and pharmacokinetics.
F. Innocenti
No relevant relationships to disclose
G. L. Rosner
Stock Ownership - Pfizer (B)
W. Qiao
No relevant relationships to disclose
A. M. de Graan
No relevant relationships to disclose
M. J. Ratain
Consultant or Advisory Role - Drais Pharmaceuticals; Mersana
Other Remuneration - University of Chicago
R. H. N. van Schaik
No relevant relationships to disclose
J. Ramirez
No relevant relationships to disclose
R. Mathijssen
No relevant relationships to disclose